ObsEva S.A. (OBSV) Research

ObsEva S.A. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for conditions affecting women's reproductive health and pregnancy. A key part of their development pipeline is Linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, currently in Phase III clinical trials. This drug aims to mitigate pain associated with endometriosis and reduce heavy menstrual bleeding stemming from uterine fibroids in pre-menopausal women. Additionally, the company is progressing Ebopiprant, a selective oral prostaglandin F2a (PGF2a) receptor antagonist, through Phase II trials as a once-daily therapy for preterm labor occurring between 24 and 34 weeks of gestation. Their portfolio also includes Nolasiban, an oral oxytocin receptor antagonist in Phase I clinical development, designed to enhance clinical pregnancy and live birth outcomes for women undergoing in vitro fertilization. Founded in 2012, ObsEva S.A. operates from its headquarters in Geneva, Switzerland.

Market snapshot

Symbol
OBSV
Price
$0.10
Day change
0.00%
Market cap
$11.0M
P/E ratio
-0.31x
52-week range
0.065-2.14
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$6.00

Peer companies

  • Applied Molecular Transport Inc. (AMTI)
  • Apexigen, Inc. (APGN)
  • Cyclacel Pharmaceuticals, Inc. (CYCC)
  • Gelesis Holdings, Inc. (GLS)
  • TuHURA Biosciences, Inc. (HURA)
  • IMV Inc. (IMVIF)
  • Korro Bio, Inc. (KRRO)
  • Millendo Therapeutics, Inc. (MLND)

Recent insider activity

  • Loumaye Ernest — P-Purchase (4000000 shares) on 2023-04-06
  • Loumaye Ernest — P-Purchase (4000000 shares) on 2023-02-28
  • Brown William Michael — A-Award (250000 shares) on 2023-02-23
  • Loumaye Ernest — trade (0 shares) on 2023-01-01
  • Mathers Edward T — trade (32000 shares) on 2023-01-01

Open ObsEva S.A. (OBSV) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.